During normal B-cell development there are sequential rearrangements in the immunoglobulin heavy chain (IgH) locus, each of which results in the joining of two non-contiguous sequences, with deletion of intervening sequences.
. The presence of contaminating D H -J H -C H DNA correlates with the inability to detect genomic changes in MGUS. (a) JH segmented copy number for the Lopez-Corral 2 (GSE31339: PB, MGUS, SMM, MM) and IFM 3 (GSE25262: IFM untreated MM, IFM relapsed MM, MOSAIC) samples was estimated using GenePattern Affymetrix SNP6 Copy Number Inference Pipeline. 4 The SNP6 CEL files were downloaded from National Center for Biotechnology Information. The samples labeled MOSAIC are dilutions of a MM tumor with germline DNA. The lowest copy number of the segmented region (X5 probes) in the D H -J H -C H region (hg18 chr14:105200000-105550000) is plotted. PB, peripheral blood. (b) The whole-genome segmented copy number is shown for the Lopez-Corral samples ordered by the degree of deletion within the D H -J H -C H region, as demonstrated by the copy number loss in the D H -J H -C H region. The sharp vertical lines, most of which are not tumor specific, represent copy number variation polymorphisms. The color scale for copy number loss (blue), diploid (white) and copy number gain (red) is shown on the bottom. result of the deletions resulting from these rearrangements, clonal B cells or plasma cells will have unique patterns of deletion in the V H yD H yJ H region of the IgH loci. At later stages of B-cell development, IgH switch recombination can reposition the V H D H J H sequence near downstream constant regions (C H ). As a result, clonal B cells or plasma cells that have undergone IgH switch recombination also will have clonal patterns of deletion in the C H region of the IgH locus. Often the B-cell specific deletions described above are large enough to be detected as a homozygous copy number loss using comparative genomic hybridization or single-nucleotide polymorphism arrays. Therefore, copy number changes in the IgH locus have the potential to provide a measure of contamination of clonal B or plasma cells with other cells.
Recently, Lopez-Corral et al. 2 reported increasing DNA copy number changes detectable in samples from patients with premalignant monoclonal gammopathy of undetermined significance (MGUS) to smoldering multiple myeloma (SMM) to multiple myeloma (MM). As shown in Figure 1a , the inability to detect homozygous, or near-homozygous, deletions within the D H -J H -C H region indicates that substantially more germline D H -J H -C H was detected in the MGUS than in SMM or MM samples they analyzed, indicative of the presence of contaminating DNA from non-tumor cells. This indicates that the purity estimate of their CD138-selected cells (SMM and MM 495%, and MGUS 490%) is inaccurate, particularly for MGUS samples. The extent of this contaminating DNA correlates with the inability to detect whole-genome changes in many MGUS samples (Figure 1b) . Therefore, their detection of increasing genomic changes between MGUS, SMM and MM likely relates more to the increasing purity of the samples than to underlying genetic differences between these diseases.
Isolation of tumor cells from bone marrow aspirates of patients with MM can achieve a purity of 90-95% by bead selection of cells expressing CD138. However, as the fraction of tumor cells from bone marrow aspirates of patients with MGUS can be 1-2 logs lower than for MM, substantial contamination of purified MGUS tumor cells with non-tumor cells is a significant problem that needs to be rigorously addressed when analyzing purified tumor cells.
Early intervention with allogeneic hematopoietic cell transplantation during chemotherapy-induced aplasia in patients with high-risk acute myeloid leukemia Allogeneic hematopoietic cell transplantation (HCT) is the only curative treatment option for most adult patients with high-risk or relapsed acute myeloid leukemia (AML), with conventional conditioning being the standard-of-care consolidation therapy for patients with cytogenetically defined high-risk AML. 1 Unfortunately, only 40-50% of patients in this category achieve a first complete remission (CR). The remaining patients experience refractory disease or early death that also applies for patients with relapsed AML. Novel strategies that allow earlier allogeneic HCT could lead to a higher number of patients being sufficiently transplanted before refractory disease develops and, most importantly, before cumulative toxicities occur during induction and salvage therapy and render patients ineligible for allogeneic HCT. In addition, reduced-intensity conditioning (RIC) regimens can be administered in older patients with AML or those who present with a reduced performance status and in whom intensive conditioning procedures may be harmful and may facilitate the initiation of conditioning therapy as early as 5-10 days after the end of cytarabine-containing induction or salvage chemotherapy. [1] [2] [3] [4] Different forms of RIC regimens have been administered showing feasibility, durable remission and acceptable transplantrelated mortality.
3,5-9 Our intent-to-treat approach included allogeneic HCT during chemotherapy-induced aplasia after a maximal reduction of 'leukemia burden'. We analyzed all sequential patients undergoing allogeneic HCT during chemotherapy-induced aplasia for primary refractory AML, high-risk or relapsed AML at our institution since the introduction of this novel concept.
We performed a retrospective, single-center cohort analysis in a study population comprising 95 patients with a median age of 52 years (range, 17-71 years). Inclusion criteria was AML diagnosis according to the current WHO criteria and first allogeneic HCT during chemotherapy-induced aplasia between December 1998 and March 2009. Patients with cord-blood, haploidentical and second allogeneic HCT were excluded from the analysis. The study was approved by the ethics committee of the Technical University 
